AIM
SGYP

Alambic Investment Management’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Alambic Investment Management’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-131,400
Closed -$612K – 738
2017
Q1 		$612K Buy
+131,400
New +$762K 0.08% 365
2016
Q2 		– Sell
-15,200
Closed -$42K – 612
2016
Q1 		$42K Buy
+15,200
New +$55K 0.01% 472

Other funds holding SGYP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alambic Investment Management's SGYP Position: Q2 2017 in Review

Alambic Investment Management sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2017, closing a stake of 131,400 shares — an estimated $612K sold.

Alambic Investment Management first reported a position in SGYP in Q1 2016 and held it in 2 quarters. The position peaked at $612K in Q1 2017. 146 funds tracked by Wall St. Rank hold SGYP as of Q2 2017.

  • Alambic Investment Management reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2017 after selling out during the quarter.
  • Alambic Investment Management sold 131,400 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2017, an estimated $612K.
  • Alambic Investment Management first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2016 and held it in 2 quarters.
  • Alambic Investment Management's Synergy Pharmaceuticals, Inc Common Stock position peaked at $612K in Q1 2017.
  • 146 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2017.

Based on Alambic Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.